{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:56:08Z","timestamp":1790916968191,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Cancer Institute of the National Institutes of Health","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background\/Purpose<\/jats:title>\n                    <jats:p>Optimal surgical management of occult breast cancer (OBC) with N2\/N3 nodal disease remains uncertain, but current National Comprehensive Cancer Network guidelines recommend mastectomy. We aimed to evaluate whether oncologic outcomes differ by local therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>We conducted an observational cohort study of patients with cT0N1-3M0 OBC treated at our institution between 2010 and 2025. We also analyzed data from patients registered in the National Cancer Database (NCDB) from 2006 to 2022. All patients included underwent neoadjuvant systemic therapy. Overall survival (OS) was estimated using Kaplan\u2013Meier methods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 85 patients treated at our institution, 42 (49.4%) had cN1 disease, 15 (17.6%) had cN2 disease, and 28 (32.9%) had cN3 disease. A total of 14 (16.5%) underwent mastectomy. Over a median follow-up of 3.6\u00a0years [IQR: 1.8, 7.9], no in-breast or chest wall recurrences occurred. The 5-year OS and disease-free survival (DFS) were similar among patients undergoing whole-breast radiation versus mastectomy, regardless of nodal status. The NCDB analysis included 632 patients, of whom 558 (88.3%) underwent mastectomy and 74 (11.7%) had radiation without breast surgery. For patients with cN2\/N3 disease, 5-year OS was 96.3% (95% CI: 77.7\u201399.9%) with whole-breast radiation versus 84.3% (95% CI: 78.3\u201389.0%) with mastectomy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There is not strong evidence for improved local control or survival with mastectomy in patients with OBC, even among those with advanced nodal disease. This lack of evidentiary support should be discussed in shared decision-making when mastectomy is presented as the default recommendation for all patients with OBC and N2\/N3 disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-20141-1","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:50:52Z","timestamp":1783345852000},"page":"9583-9591","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Is Mastectomy Necessary in Patients with Occult Breast Cancer and Advanced (N2\/N3) Nodal Disease?"],"prefix":"10.1245","volume":"33","author":[{"given":"Courtney M.","family":"Lattimore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerollos Nashat","family":"Wanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry M.","family":"Kuerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly K.","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon H.","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa P.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona F.","family":"Shaitelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Tamirisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen M.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"issue":"17","key":"20141_CR1","doi-asserted-by":"publisher","first-page":"4000","DOI":"10.1002\/cncr.25197","volume":"116","author":"GV Walker","year":"2010","unstructured":"Walker GV, Smith GL, Perkins GH, et al. Population-based analysis of occult primary breast cancer with axillary lymph node metastasis. Cancer. 2010;116(17):4000\u20136. https:\/\/doi.org\/10.1002\/cncr.25197.","journal-title":"Cancer."},{"issue":"1","key":"20141_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10549-019-05285-x","volume":"177","author":"HM Johnson","year":"2019","unstructured":"Johnson HM, Irish W, Vohra NA, Wong JH. The effect of local therapy on breast cancer-specific mortality of women with occult breast cancer and advanced nodal disease (N2\/N3): a population analysis. Breast Cancer Res Treat. 2019;177(1):155\u201364. https:\/\/doi.org\/10.1007\/s10549-019-05285-x.","journal-title":"Breast Cancer Res Treat."},{"key":"20141_CR3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.breast.2020.10.012","volume":"54","author":"A Ofri","year":"2020","unstructured":"Ofri A, Moore K. Occult breast cancer: where are we at? The Breast. 2020;54:211\u20135. https:\/\/doi.org\/10.1016\/j.breast.2020.10.012.","journal-title":"The Breast"},{"issue":"10","key":"20141_CR4","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1245\/s10434-017-5928-x","volume":"24","author":"LK Hessler","year":"2017","unstructured":"Hessler LK, Molitoris JK, Rosenblatt PY, et al. Factors influencing management and outcome in patients with occult breast cancer with axillary lymph node involvement: analysis of the National Cancer Database. Ann Surg Oncol. 2017;24(10):2907\u201314. https:\/\/doi.org\/10.1245\/s10434-017-5928-x.","journal-title":"Ann Surg Oncol."},{"issue":"6","key":"20141_CR5","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1245\/s10434-016-5104-8","volume":"23","author":"FI Macedo","year":"2016","unstructured":"Macedo FI, Eid JJ, Flynn J, Jacobs MJ, Mittal VK. Optimal surgical management for occult breast carcinoma: a meta-analysis. Ann Surg Oncol. 2016;23(6):1838\u201344. https:\/\/doi.org\/10.1245\/s10434-016-5104-8.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"20141_CR6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","volume":"35","author":"EG Committee","year":"2024","unstructured":"Committee EG, Loibl S, Andr\u00e9 F, et al. Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Annals Oncol. 2024;35(2):159\u201382. https:\/\/doi.org\/10.1016\/j.annonc.2023.11.016.","journal-title":"Annals Oncol."},{"issue":"3","key":"20141_CR7","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s10549-024-07604-3","volume":"210","author":"E Vicini","year":"2025","unstructured":"Vicini E, Galimberti V, Leonardi MC, et al. Shifting from axillary dissection to targeted axillary surgery after neoadjuvant treatment: the evolving management of occult breast cancer in a monoinstitutional series of 114 patients. Breast Cancer Res Treat. 2025;210(3):661\u201372. https:\/\/doi.org\/10.1007\/s10549-024-07604-3.","journal-title":"Breast Cancer Res Treat."},{"issue":"4","key":"20141_CR8","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.amjsurg.2005.06.026","volume":"190","author":"AK Khandelwal","year":"2005","unstructured":"Khandelwal AK, Garguilo GA. Therapeutic options for occult breast cancer: a survey of the American society of breast surgeons and review of the literature. Am J Surg. 2005;190(4):609\u201313. https:\/\/doi.org\/10.1016\/j.amjsurg.2005.06.026.","journal-title":"Am J Surg."},{"issue":"2","key":"20141_CR9","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.surg.2023.03.020","volume":"174","author":"AC Holt","year":"2023","unstructured":"Holt AC, Haji F, McCloskey S, Baker JL. De-escalation of surgery for occult breast cancer with axillary metastasis. Surgery. 2023;174(2):410\u20132. https:\/\/doi.org\/10.1016\/j.surg.2023.03.020.","journal-title":"Surgery."},{"key":"20141_CR10","unstructured":"NCCN Guidelines Version 5.2025 Breast Cancer. Updated 2025. Accessed January 4, 2026, https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf"},{"issue":"12","key":"20141_CR11","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1245\/aso.2005.03.520","volume":"12","author":"CL Buchanan","year":"2005","unstructured":"Buchanan CL, Morris EA, Dorn PL, Borgen PI, Van Zee KJ. Utility of breast magnetic resonance imaging in patients with occult primary breast cancer. Ann Surg Oncol. 2005;12(12):1045\u201353. https:\/\/doi.org\/10.1245\/aso.2005.03.520.","journal-title":"Ann Surg Oncol."},{"issue":"7","key":"20141_CR12","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1002\/1097-0142(19901001)66:7<1461::AID-CNCR2820660704>3.0.CO;2-Z","volume":"66","author":"N Ellerbroek","year":"1990","unstructured":"Ellerbroek N, Holmes F, Singletary E, Evans H, Oswald M, McNeese M. Treatment of patients with isolated axillary nodal metastases from an occult primary carcinoma consistent with breast origin. Cancer. 1990;66(7):1461\u20137. https:\/\/doi.org\/10.1002\/1097-0142(19901001)66:7%3c1461::AID-CNCR2820660704%3e3.0.CO;2-Z.","journal-title":"Cancer."},{"issue":"1","key":"20141_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00000658-190707000-00001","volume":"46","author":"WS Halsted","year":"1907","unstructured":"Halsted WS. The results of radical operations for the cure of carcinoma of the breast. Ann Surg. 1907;46(1):1\u201319.","journal-title":"Ann Surg."},{"issue":"5","key":"20141_CR14","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/0046-8177(90)90008-S","volume":"21","author":"PP Rosen","year":"1990","unstructured":"Rosen PP, Kimmel M. Occult breast carcinoma presenting with axillary lymph node metastases: a follow-up study of 48 patients. Human Pathol. 1990;21(5):518\u201323. https:\/\/doi.org\/10.1016\/0046-8177(90)90008-S.","journal-title":"Human Pathol"},{"issue":"2","key":"20141_CR15","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ejso.2009.09.007","volume":"36","author":"J de Bresser","year":"2010","unstructured":"de Bresser J, de Vos B, van der Ent F, Hulsew\u00e9 K. Breast MRI in clinically and mammographically occult breast cancer presenting with an axillary metastasis: a systematic review. Eur J Surg Oncol. 2010;36(2):114\u20139. https:\/\/doi.org\/10.1016\/j.ejso.2009.09.007.","journal-title":"Eur J Surg Oncol."},{"issue":"2","key":"20141_CR16","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1148\/radiology.212.2.r99au40543","volume":"212","author":"SG Orel","year":"1999","unstructured":"Orel SG, Weinstein SP, Schnall MD, et al. Breast MR imaging in patients with axillary node metastases and unknown primary malignancy. Radiology. 1999;212(2):543\u20139. https:\/\/doi.org\/10.1148\/radiology.212.2.r99au40543.","journal-title":"Radiology."},{"issue":"2","key":"20141_CR17","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1148\/radiology.205.2.9356625","volume":"205","author":"EA Morris","year":"1997","unstructured":"Morris EA, Schwartz LH, Dershaw DD, van Zee KJ, Abramson AF, Liberman L. MR imaging of the breast in patients with occult primary breast carcinoma. Radiology. 1997;205(2):437\u201340. https:\/\/doi.org\/10.1148\/radiology.205.2.9356625.","journal-title":"Radiology."},{"issue":"1","key":"20141_CR18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.amjsurg.2019.11.023","volume":"220","author":"C Tsai","year":"2020","unstructured":"Tsai C, Zhao B, Chan T, Blair SL. Treatment for occult breast cancer: a propensity score analysis of the National Cancer Database. Am J Surg. 2020;220(1):153\u201360. https:\/\/doi.org\/10.1016\/j.amjsurg.2019.11.023.","journal-title":"Am J Surg."},{"issue":"5","key":"20141_CR19","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s10434-001-0425-6","volume":"8","author":"G Vlastos","year":"2001","unstructured":"Vlastos G, Jean ME, Mirza AN, et al. Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases. Ann Surg Oncol. 2001;8(5):425\u201331. https:\/\/doi.org\/10.1007\/s10434-001-0425-6.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"20141_CR20","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1245\/s10434-014-3991-0","volume":"22","author":"NM Rueth","year":"2015","unstructured":"Rueth NM, Black DM, Limmer AR, et al. Breast conservation in the setting of contemporary multimodality treatment provides excellent outcomes for patients with occult primary breast cancer. Ann Surg Oncol. 2015;22(1):90\u20135. https:\/\/doi.org\/10.1245\/s10434-014-3991-0.","journal-title":"Ann Surg Oncol."},{"issue":"11","key":"20141_CR21","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1245\/s10434-017-5965-5","volume":"24","author":"DP McCartan","year":"2017","unstructured":"McCartan DP, Zabor EC, Morrow M, Van Zee KJ, El-Tamer MB. Oncologic outcomes after treatment for MRI occult breast cancer (pT0N+). Ann Surg Oncol. 2017;24(11):3141\u20137. https:\/\/doi.org\/10.1245\/s10434-017-5965-5.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"20141_CR22","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s10549-024-07500-w","volume":"209","author":"M LaBella","year":"2025","unstructured":"LaBella M, Lile-King RE, Agala CB, et al. Trends in management and related outcomes for occult primary breast cancer. Breast Cancer Res Treat. 2025;209(2):367\u201374. https:\/\/doi.org\/10.1007\/s10549-024-07500-w.","journal-title":"Breast Cancer Res Treat."},{"key":"20141_CR23","unstructured":"Residual Cancer Burden Calculator. Accessed December 5, 2025, 2025. https:\/\/www3.mdanderson.org\/app\/medcalc\/index.cfm?pagename=jsconvert3"},{"issue":"4","key":"20141_CR24","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1093\/biostatistics\/kxt016","volume":"14","author":"MP Fay","year":"2013","unstructured":"Fay MP, Brittain EH, Proschan MA. Pointwise confidence intervals for a survival distribution with small samples or heavy censoring. Biostatistics. 2013;14(4):723\u201336. https:\/\/doi.org\/10.1093\/biostatistics\/kxt016.","journal-title":"Biostatistics."},{"issue":"7","key":"20141_CR25","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1245\/s10434-018-6486-6","volume":"25","author":"AE Giuliano","year":"2018","unstructured":"Giuliano AE, Edge SB, Hortobagyi GN. Eighth edition of the AJCC cancer staging manual: breast cancer. Ann Surg Oncol. 2018;25(7):1783\u20135. https:\/\/doi.org\/10.1245\/s10434-018-6486-6.","journal-title":"Ann Surg Oncol."},{"issue":"10","key":"20141_CR26","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1245\/s10434-016-5408-8","volume":"23","author":"JC Boughey","year":"2016","unstructured":"Boughey JC, Attai DJ, Chen SL, et al. Contralateral prophylactic mastectomy consensus statement from the American society of breast surgeons: additional considerations and a framework for shared decision making. Ann Surg Oncol. 2016;23(10):3106\u201311. https:\/\/doi.org\/10.1245\/s10434-016-5408-8.","journal-title":"Ann Surg Oncol."},{"issue":"4","key":"20141_CR27","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1245\/s10434-024-14893-x","volume":"31","author":"P Singh","year":"2024","unstructured":"Singh P, Agnese D, Amin M, et al. Society of surgical oncology breast disease site working group statement on contralateral mastectomy: indications, outcomes, and risks. Ann Surg Oncol. 2024;31(4):2212\u201323. https:\/\/doi.org\/10.1245\/s10434-024-14893-x.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"20141_CR28","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1245\/s10434-025-18474-4","volume":"33","author":"JL Sturz-Ellis","year":"2026","unstructured":"Sturz-Ellis JL, Vetter CD, Day CN, Boughey JC. A systematic review of occult malignancy and sentinel lymph node metastasis at the time of contralateral prophylactic mastectomy. Ann Surg Oncol. 2026;33(2):1162\u201370. https:\/\/doi.org\/10.1245\/s10434-025-18474-4.","journal-title":"Ann Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20141-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20141-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20141-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:50:31Z","timestamp":1790916631000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-20141-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["20141"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20141-1","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"24 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KKH: Medical Advisory Board\u2014ArmadaHealth, AstraZeneca, Daiichi Sankyo; Honorarium from Springer Nature\u2014Editor-in-Chief Current Breast Cancer Reports; Research funding to MD Anderson Cancer Center\u2014Cairn Surgical, Eli Lilly & Co., Lumicell; Paid travel\u2014Merck & Co. SHG: Komen SAC 150061. SS: Contracted research support from: Artidis, Radionetics, ExactSciences, Lumicell. Grant from NIH\/NCI. This study was supported, in part, by the National Cancer Institute of the National Institutes of Health under award number P30 CA016672.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}}]}}